All In Biotech

Drug Trial Radar · NCT06956235

Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Moderate to Severe Hidradenitis Suppurativa

Last checked: Nov 19, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 149 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

149

Actual

Start

Jun 9, 2025

Primary completion

Apr 2, 2026

Study completion Jun 6, 2028

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
May 4, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 2b randomized, double-blind, placebo-controlled study of the safety and efficacy of tulisokibart in participants with moderate to severe hidradenitis suppurativa. The primary hypothesis is that at least 1 dose of tulisokibart is superior to placebo with respect to the proportion of participants achieving a 50% reduction in Hidradenitis Suppurativa Clinical Response (HiSCR50) at Week 16 (ie, at end of double-blind treatment).

Conditions

  • Hidradenitis Suppurativa

Interventions

  • TulisokibartDrug

    Solution in autoinjector for subcutaneous (SC) injection

  • PlaceboDrug

    Solution in autoinjector for SC injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) 50 at Week 16Time frame: Week 16

Locations

68 sites in 15 countries. Site status is shown where the registry gives one.

  • Cahaba Dermatology & Skin Health Center ( Site 0012)

    Birmingham, Alabama

  • Medical Dermatology Specialists ( Site 0027)

    Phoenix, Arizona

  • Northwest Arkansas Clinical Trials Center, PLLC ( Site 0049)

    Rogers, Arkansas

  • Northridge Clinical Trials ( Site 0004)

    Northridge, California

  • Integrative Skin Science and Research ( Site 0015)

    Sacramento, California

  • Olympian Clinical Research ( Site 0010)

    Tampa, Florida

  • Skin Care Physicians of Georgia ( Site 0033)

    Macon, Georgia

  • Dawes Fretzin Clinical Research Group, LLC ( Site 0025)

    Indianapolis, Indiana

  • Beth Israel Deaconess Medical Center ( Site 0044)

    Boston, Massachusetts

  • Revival Research Institute, LLC ( Site 0005)

    Troy, Michigan

  • Mount Sinai Doctors - East 85th Street ( Site 0050)

    New York, New York

  • DJL Clinical Research, PLLC ( Site 0021)

    Charlotte, North Carolina

  • University Hospitals Cleveland Medical Center ( Site 0046)

    Cleveland, Ohio

  • Wright State Physicians Health Center ( Site 0041)

    Fairborn, Ohio

  • Palmetto Clinical Trial Services, LLC ( Site 0023)

    Anderson, South Carolina

  • Arlington Center for Dermatology ( Site 0045)

    Arlington, Texas

  • Texas Dermatology Research Center ( Site 0019)

    Dallas, Texas

  • Reveal Research Institute ( Site 0018)

    Frisco, Texas

  • Progressive Clinical Research ( Site 0020)

    San Antonio, Texas

  • CIPREC ( Site 0202)

    CABA, Argentina

  • Hospital Italiano de Buenos Aires ( Site 0205)

    CABA, Argentina

  • Psoriahue ( Site 0203)

    CABA, Argentina

  • Derma Internacional SA ( Site 0206)

    CABA, Argentina

  • Liverpool Hospital ( Site 1403)

    Liverpool, New South Wales, Australia

  • The Alfred Hospital ( Site 1401)

    Melbourne, Victoria, Australia

  • Fremantle Dermatology ( Site 1402)

    Fremantle, Western Australia, Australia

  • Wiseman Dermatology Research Inc. ( Site 0107)

    Winnipeg, Manitoba, Canada

  • Brunswick Dermatology Center ( Site 0101)

    Frederiction, New Brunswick, Canada

  • Lynderm Research Inc. ( Site 0104)

    Markham, Ontario, Canada

  • SKiN Centre for Dermatology ( Site 0103)

    Peterborough, Ontario, Canada

  • York Dermatology Clinic & Research Centre ( Site 0106)

    Richmond Hill, Ontario, Canada

  • Centro Skin Med Limitada ( Site 0305)

    Santiago, Region M. de Santiago, Chile

  • Clinica Dermacross ( Site 0301)

    Santiago, Region M. de Santiago, Chile

  • Centro Internacional de Estudios Clinicos (CIEC) ( Site 0302)

    Santiago, Region M. de Santiago, Chile

  • Dermatology Hospital of Southern Medical University ( Site 1504)

    Guangzhou, Guangdong, China

  • The Second Xiangya Hospital of Central South University ( Site 1505)

    Changsha, Hunan, China

  • The First Hospital of Jilin University ( Site 1502)

    Changchun, Jilin, China

  • Ruijin Hospital Shanghai Jiaotong University School of Medicine ( Site 1515)

    Shanghai, Shanghai Municipality, China

  • Huashan Hospital of Fudan University ( Site 1506)

    Shanghai, Shanghai Municipality, China

  • PEOPLE'S HOSPITAL OF XINJIANG UYGUR AUTONOMOUS REGION ( Site 1509)

    Ürümqi, Xinjiang, China

Showing 40 of 68 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.